Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
May 2019
Historique:
received: 11 01 2019
revised: 27 03 2019
accepted: 15 04 2019
entrez: 17 5 2019
pubmed: 17 5 2019
medline: 23 5 2019
Statut: ppublish

Résumé

Ovarian cancer (OC) is the 5th most common cancer among European women. Approximately 70-80% of OC is diagnosed at advanced stage resulting in an elevated mortality rate. The aim of this study was to examine whether Annexin A2 and S100A10 expression can be used as prognostic markers for epithelial ovarian cancer (EOC). Expression of Annexin A2 and S100A10 was evaluated in EOC tissue samples (n=303) by immunohistochemistry. The staining of the membrane, cytoplasmic and stroma was assessed according to intensity. The expression of both markers correlated to histological subtype, histological grading, International Federation of Gynecology and Obstetrics (FIGO) stage, and macro-radical surgery. Univariate Cox regression analysis showed that Annexin A2 and S100A10 in stromal tissue correlated with shorter overall survival (OS). Multivariate Cox regression analysis demonstrated no independent prognostic significance of stromal Annexin A2 expression. High expression of Annexin A2 and S100A10 in stromal tissue from EOC patients was associated with reduced OS; however, no independent prognostic value was found for any of the markers.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Ovarian cancer (OC) is the 5th most common cancer among European women. Approximately 70-80% of OC is diagnosed at advanced stage resulting in an elevated mortality rate. The aim of this study was to examine whether Annexin A2 and S100A10 expression can be used as prognostic markers for epithelial ovarian cancer (EOC).
MATERIALS AND METHODS METHODS
Expression of Annexin A2 and S100A10 was evaluated in EOC tissue samples (n=303) by immunohistochemistry. The staining of the membrane, cytoplasmic and stroma was assessed according to intensity.
RESULTS RESULTS
The expression of both markers correlated to histological subtype, histological grading, International Federation of Gynecology and Obstetrics (FIGO) stage, and macro-radical surgery. Univariate Cox regression analysis showed that Annexin A2 and S100A10 in stromal tissue correlated with shorter overall survival (OS). Multivariate Cox regression analysis demonstrated no independent prognostic significance of stromal Annexin A2 expression.
CONCLUSION CONCLUSIONS
High expression of Annexin A2 and S100A10 in stromal tissue from EOC patients was associated with reduced OS; however, no independent prognostic value was found for any of the markers.

Identifiants

pubmed: 31092442
pii: 39/5/2475
doi: 10.21873/anticanres.13367
doi:

Substances chimiques

Annexin A2 0
Biomarkers, Tumor 0
S100 Proteins 0
S100 calcium binding protein A10 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2475-2482

Informations de copyright

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Maria V Christensen (MV)

Department of Pathology, Molecular Unit, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

Claus Høgdall (C)

Department of Gynaecology, Juliane Maria Centre (JMC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Steffen G Jensen (SG)

Department of Pathology, Molecular Unit, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

Noor Lokman (N)

Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, Australia.

Carmela Ricciardelli (C)

Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, The University of Adelaide, Adelaide, Australia.

Ib J Christensen (IJ)

Department of Pathology, Molecular Unit, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

Pernille Christiansen (P)

Department of Pathology, Diagnostic Centre, Rigshospitalet, Copenhagen, Denmark.

Julie Brask (J)

Department of Pathology, Diagnostic Centre, Rigshospitalet, Copenhagen, Denmark.

Mona A Karlsen (MA)

Department of Gynaecology, Juliane Maria Centre (JMC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Therese K Nissen (TK)

Department of Gynaecology and Obstetrics, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
Ditzel Group, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.

Kirsten M Jochumsen (KM)

Department of Gynaecology and Obstetrics, Odense University Hospital, University of Southern Denmark, Odense, Denmark.

Estrid Høgdall (E)

Department of Pathology, Molecular Unit, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark estrid.hoegdall@regionh.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH